2005
DOI: 10.1111/j.1365-2036.2005.02516.x
|View full text |Cite
|
Sign up to set email alerts
|

Rifaximin dose‐finding study for the treatment of small intestinal bacterial overgrowth

Abstract: SUMMARYBackground: Few controlled studies assessing choice and duration of antibiotic therapy for small intestinal bacterial overgrowth are available. Aim: To assess efficacy, safety and tolerability of different doses of rifaximin, a broad spectrum non-absorbable antibiotic, for intestinal bacterial overgrowth eradication. Methods: We enrolled 90 consecutive patients affected by small intestinal bacterial overgrowth. The presence of small intestinal bacterial overgrowth was based on the occurrence of a rise o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
79
1
6

Year Published

2006
2006
2018
2018

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 108 publications
(90 citation statements)
references
References 18 publications
(24 reference statements)
4
79
1
6
Order By: Relevance
“…The GI tract can also contain substantial amounts of H 2 (38). Bacteria were grown in pH-and temperature-regulated bioreactors using glucose as the sole and limiting carbon source (pH 7, 37°C, 30 mM glucose).…”
Section: Analysis Of Central Carbon Metabolism In Early Grown Bmentioning
confidence: 99%
“…The GI tract can also contain substantial amounts of H 2 (38). Bacteria were grown in pH-and temperature-regulated bioreactors using glucose as the sole and limiting carbon source (pH 7, 37°C, 30 mM glucose).…”
Section: Analysis Of Central Carbon Metabolism In Early Grown Bmentioning
confidence: 99%
“…In a recent dose-finding study [61], performed to assess the efficacy of rifaximin in the treatment of small intestine bacterial overgrowth (SIBO), it was found that 70% of these patients were H. pylori -positive. This observation gave the opportunity to evaluate simultaneously the disappearance of SIBO and the eradication of the microorganism.…”
Section: In Vivo Helicobacter Pylori Eradication Trialsmentioning
confidence: 99%
“…1 Rifaximin dose-response curves for decontamination of SIBO (y = –13.571 + 6.6429e-2x, r 2 = 1.000) and eradication of H. pylori (y = –6.5714 + 3.1429e-2x, r 2 = 0.910) in the same (n = 63 out of 90) patients (from data in Lauritano et al [61] and unpublished data by the same authors). …”
Section: In Vivo Helicobacter Pylori Eradication Trialsmentioning
confidence: 99%
“…Since rifaximin was found to be active against H. pylori strains resistant to clarithromycin [31] , it was speculated that this antibiotic could be associated in vivo with this antimicrobial [26] . In a previous investigation [24] , it was shown that monotherapy with rifaximin provides an eradication rate of 37%, that is substantially higher than previously reported for single antimicrobial therapy (with the exception of clarithromycin). The association in a dual regimen with other antimicrobial drugs achieved an eradication rate ranging from 40% in association with colloidal bismuth subcitrate to 62% in association with metronidazole [29] .…”
Section: Discussionmentioning
confidence: 69%
“…Moreover, there is increasing evidence suggesting that rifaximin represents an effective treatment option for small intestinal bacterial overgrowth [23,24] .…”
Section: Introductionmentioning
confidence: 99%